Vanqua Bio Will Use $85M Funding to Advance New Tech Platform

Vanqua Bio Will Use $85M Funding to Advance New Tech Platform

308139

Vanqua Bio Will Use $85M Funding to Advance New Tech Platform

Vanqua Bio has raised $85 million in funding to accelerate the development of its small molecule technology platform for treating neurodegenerative disorders such as Parkinson’s disease. Led by Omega Funds, the Series B financing will advance the research of Dimitri Krainc, MD, PhD, of Northwestern University, an expert on molecular pathways underlying neurodegenerative diseases. Researchers are hoping to develop next-generation small molecule therapies for Parkinson’s and other diseases, including Gaucher, Alzheimer’s, and amyotrophic lateral sclerosis…

You must be logged in to read/download the full post.